V. A. Dudin

[The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis].

A. Boyko, K. Bakhtiyarova, N. Malkova, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].

S. Sivertseva, M. Zakharova, O. Boyko, 2023, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.

[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

O. Boyko, N. Totolyan, F. Khabirov, 2022, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.